Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...
atai Life Sciences (ATAI) reported promising data on Tuesday from the second part of a mid-stage trial of BPL-003, a psychedelic therapy being developed by Beckley Psytech, for treatment-resistant ...
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global ...
Wave Life Sciences Ltd. (NASDAQ:WVE) released data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon-skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy ...
The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results